Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

A number of other brokerages also recently issued reports on AIMT. Wedbush reissued an “outperform” rating and issued a $70.00 price target on shares of Aimmune Therapeutics in a report on Friday, December 1st. ValuEngine downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Piper Jaffray Companies upped their price objective on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an “overweight” rating in a research report on Tuesday. Roth Capital assumed coverage on shares of Aimmune Therapeutics in a research report on Monday, November 20th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Credit Suisse Group upped their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Aimmune Therapeutics has a consensus rating of “Hold” and an average price target of $53.80.

Shares of Aimmune Therapeutics (AIMT) traded down $0.92 during trading on Wednesday, hitting $35.36. 317,370 shares of the stock were exchanged, compared to its average volume of 354,939. Aimmune Therapeutics has a 52-week low of $15.97 and a 52-week high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. research analysts predict that Aimmune Therapeutics will post -2.57 EPS for the current year.

In related news, CEO Stephen George Dilly sold 1,154 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $26.24, for a total value of $30,280.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Susan E. Barrowcliffe sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $25.00, for a total transaction of $500,000.00. Following the completion of the transaction, the insider now owns 20,000 shares in the company, valued at $500,000. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 304,986 shares of company stock worth $8,208,100. 17.59% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. increased its position in shares of Aimmune Therapeutics by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock worth $1,892,000 after purchasing an additional 4,788 shares during the last quarter. GSA Capital Partners LLP bought a new position in Aimmune Therapeutics during the second quarter valued at approximately $442,000. Goldman Sachs Group Inc. grew its position in Aimmune Therapeutics by 139.9% during the second quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock valued at $4,675,000 after acquiring an additional 132,603 shares during the last quarter. Bank of New York Mellon Corp grew its position in Aimmune Therapeutics by 16.9% during the second quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock valued at $2,700,000 after acquiring an additional 19,016 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in Aimmune Therapeutics during the second quarter valued at approximately $360,000. Institutional investors own 73.34% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Aimmune Therapeutics (AIMT) Lowered to “Hold” at Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/06/aimmune-therapeutics-aimt-lowered-to-hold-at-zacks-investment-research.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.